期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 16, 期 6, 页码 601-614出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1174577
关键词
Antipsychotic; schizophrenia; dopamine D2 receptors; dopamine receptor phosphoprotein modulator; NMDA receptors; serotonin reuptake transporter; efficacy; safety; 5HT2a receptors; neuropsychiatric disorders
资金
- Intracellular Therapies
- Bristol-Myers Squibb
- Otsuka
- Takeda
- Teva
ITI-007 is an investigational drug being developed for schizophrenia and other neuropsychiatric/neurodegenerative diseases. ITI-007 has a unique pharmacological profile, combining potent 5-HT2a receptor antagonism with cell-type-specific dopamine and glutamate receptor modulation, plus serotonin reuptake inhibition. At dopamine-D2 receptors, ITI-007 acts as a post-synaptic antagonist and pre-synaptic partial agonist. Additionally, ITI-007 stimulates phosphorylation of glutamatergic NMDA-NR2B receptors, downstream of dopamine-D1 receptor intracellular signaling. Based on a large, placebo and risperidone controlled, Phase-II trial, ITI-007 60 mg was shown to be effective in reducing symptoms in patients with acutely exacerbated schizophrenia. The antipsychotic efficacy of ITI-007 60 mg in this patient population was confirmed in a recently completed Phase III study. ITI-007 was associated with minimal safety risk compared to risperidone (Phase II study) or placebo (both studies) for neuromotor disturbances, prolactin changes, weight gain and metabolic abnormalities. A second 6-week, placebo and risperidone-controlled Phase-III trial in acutely exacerbated schizophrenia is ongoing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据